Search Results
Your search for ,foR matches 32393 pages
Showing 20651 - 20700ASCO Makes No Changes to 2014 Recommendations for Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer
As reported in the Journal of Clinical Oncology by Gary H. Lyman, MD, of Fred Hutchinson Cancer Research Center, and colleagues, an ASCO clinical practice guideline update panel made no changes to the 2014 recommendations for sentinel lymph node biopsy in women with early-stage breast cancer. The...
ESMO Asia 2016: Asian Patients With Head and Neck Squamous Cell Carcinoma Live Longer With Immunotherapy Than Overall Population
Asian patients with head and neck cancer live longer with pembrolizumab (Keytruda) immunotherapy than the overall population, according to a subanalysis of the KEYNOTE-012 trial presented at the ESMO Asia 2016 Congress in Singapore. “Head and neck squamous cell carcinoma is the seventh most...
Circulating Tumor DNA May Serve as a Prognostic Marker in Pancreatic Cancer
Translational research in pancreatic adenocarcinoma has been limited by the difficulty of obtaining sufficient quality and quantity tumor tissue from patients. A study by Pietrasz et al assessing the feasibility and prognostic value of circulating tumor DNA (ctDNA) in pancreatic adenocarcinoma has...
Study Finds Regorafenib Improves Survival in Patients With Hepatocelluar Carcinoma Progressing on Sorafenib
Regorafenib (Stivarga) improved overall survival vs placebo in patients with hepatocellular carcinoma who had experienced disease progression on sorafenib (Nexavar) treatment, according to the phase III RESORCE trial reported by Bruix et al in The Lancet. Study Details In this double-blind trial, ...
ESMO Asia 2016: Almost 20% of Swedish Breast Cancer Patients Fail to Complete Prescribed Endocrine Therapy
Around 20% of patients with breast cancer in Sweden do not complete endocrine therapy, according to research that will be reported at the ESMO Asia 2016 Congress (Abstract 62O_PR), to be held December 16–19 in Singapore.The study in over 5,500 women found that younger patients and those who...
Effectiveness of Electroacupuncture for Sleep Disturbances in Patients With Breast Cancer and Hot Flashes
Studies suggest that approximately 30% to 40% of women with breast cancer report persistent hot flashes. Nocturnal hot flashes are among the most problematic because they can contribute to poor sleep. A new study published by Garland et al in Menopause shows that electroacupuncture may be effective ...
Addition of Adjuvant Chemotherapy to Chemoradiotherapy Achieves Best Survival Results in Locally Advanced Nasopharyngeal Carcinoma
In an individual patient-data meta-analysis reported in the Journal of Clinical Oncology, Ribassin-Majed et al in the Meta-analysis of Chemotherapy in Nasopharyngeal Collaborative Group found that the addition of adjuvant chemotherapy to chemoradiotherapy was associated with the greatest overall...
Effect of Inpatient Palliative Care on Quality of Life After Stem Cell Transplant
Integrating palliative care into the treatment of patients undergoing hematopoietic stem cell transplantation for cancers like leukemia and lymphoma can improve their quality of life, relieve symptoms associated with the procedure, and reduce depression and anxiety, not only during the 3- to 4-week ...
Monica M. Bertagnolli, MD, Elected ASCO President for 2018–2019 Term
Monica M. Bertagnolli, MD, a long-time ASCO member and volunteer, has been elected to serve as the President of ASCO for the term beginning in June 2018. She will take office as President-Elect during the ASCO Annual Meeting in Chicago in June 2017. Additionally, three new members were elected to...
WCLC 2016: Icotinib May Improve Progression-Free Survival vs Whole-Brain Irradiation in Patients With NSCLC With Brain Metastases
Patients whose lung cancer spreads to their brain typically have only 4 to 6 months left to live, but research presented by Chinese doctors suggests that using icotinib increases progression-free survival in these patients compared to whole-brain irradiation and chemotherapy combined. Yi-Long Wu,...
WCLC 2016: First-Line Ceritinib Reduces Risk of Disease Progression in ALK-Positive NSCLC vs Chemotherapy
Patients who received first-line ceritinib experienced a 45% risk reduction for advanced anaplastic lymphoma kinase (ALK)–positive on–small cell lung cancer (NSCLC) compared to a control group that received chemotherapy, according to research presented at the IASLC 17th World...
WCLC 2016: New Lung Cancer Tumor Staging Manual to Shape Clinical Treatment
A revised tumor classification based on more than 70,000 non–small cell lung cancer patients and 6,100 small cell lung cancer patients is now available to lung cancer specialists around the world in the form of the 8th edition of the tumor, node, and metastasis (TNM) classification. The...
ASCO Clinical Practice Guideline on Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers
As reported in the Journal of Clinical Oncology by Saro H. Armenian, DO, MPH, of City of Hope, and colleagues, ASCO has released a clinical practice guideline on prevention and monitoring of cardiac dysfunction in survivors of adult cancers. Recommendations were developed by an expert panel using a ...
ESMO Asia 2016: Patients in India Wait an Average of 4 Months Before Seeking a Cancer Diagnosis
Patients in Chandigarh, India, waited an average of 4 months before seeking a cancer diagnosis, according to a recent study. Some patients waited less than a week before seeing a doctor—while others waited 3 years. The researchers will report their findings at the ESMO Asia 2016 Congress ...
WCLC 2016: Phase II LUME-Meso Trial on Oral Nintedanib in Mesothelioma Demonstrates Meaningful Clinical Benefit
The LUME-Meso phase II trial in patients with unresectable malignant pleural mesothelioma met its primary endpoint of progression-free survival. The data, presented at the 17th IASLC World Conference on Lung Cancer (WCLC) in Vienna (Abstract 4191 #OA22.02), showed nintedanib (Ofev) plus...
Promising Activity Seen With First-Line Nivolumab Plus Ipilimumab in Advanced Non–Small Cell Lung Cancer
As reported in The Lancet Oncology by Hellman et al, the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) showed promising activity as first-line treatment in patients in the non–small cell lung cancer (NSCLC) cohort of the phase I CheckMate 012 study. Study Details In the...
Osimertinib Improves Progression-Free Survival vs Platinum/Pemetrexed in EGFR T790M–Positive NSCLC
In the phase III AURA3 trial reported in The New England Journal of Medicineby Mok et al, osimertinib (Tagrisso) significantly improved progression-free survival (PFS) vs platinum/pemetrexed (Alimta) among patients with epidermal growth factor receptor (EGFR) T790M–positive non–small...
ASCO CEO Dr. Clifford Hudis Commends President Obama, Vice President Biden, and Congress During 21st Century Cures Act Signing Ceremony
On Tuesday, December 13, President Obama signed into law the 21st Century Cures Act, landmark legislation designed to improve and accelerate the pace of biomedical research in the United States. ASCO Chief Executive Officer Clifford Hudis, MD, FACP, FASCO, attended the White House signing ceremony...
Rucaparib Appears Effective in Relapsed Platinum-Sensitive High-Grade Ovarian Carcinoma
In part 1 of the phase II ARIEL2 trial reported in The Lancet Oncology, Swisher et al found that the poly (ADP-ribose) polymerase (PARP) inhibitor rucaparib was associated with prolonged progression-free survival among patients with relapsed platinum-sensitive high-grade ovarian carcinoma who had...
Phase III Trial Shows Improved Progression-Free Survival With Fulvestrant vs Anastrozole in Hormone Receptor–Positive Advanced Breast Cancer
In the international phase III FALCON trial reported in The Lancet, Robertson et al found that progression-free survival was improved with intramuscular fulvestrant (Faslodex) vs oral anastrozole in endocrine therapy–naive women with hormone receptor–positive locally advanced or...
SABCS 2016: IBM Watson for Oncology Platform Shows High Degree of Concordance With Physician Recommendations
The artificial-intelligence platform Watson for Oncology (WFO) achieved a high degree of concordance with the recommendations of a panel of oncologists in a double-blinded validation study, according to results presented at the 2016 San Antonio Breast Cancer Symposium, held December 6 to 10...
SABCS 2016: Aromatase Inhibitors Were Associated With Reduced Endothelial Function in Postmenopausal Breast Cancer Patients
Postmenopausal women with breast cancer who took aromatase inhibitors demonstrated endothelial dysfunction, a predictor of cardiovascular disease, according to study results presented at the 2016 San Antonio Breast Cancer Symposium, held December 6 to 10 (Abstract s5-07). Aromatase inhibitors are...
Monica Morrow, MD: Brinker Award Lecture Summary on Changing Paradigms in Local Therapy of Breast Cancer
Monica Morrow, MD, of Memorial Sloan Kettering Cancer Center, recognized at this year’s meeting for scientific distinction in clinical research, summarizes her Brinker Award lecture on modifying local therapy to decrease the burden of cancer treatment.
S.P. Somashekhar, MBBS, MCh(Onco), on Watson for Oncology: A Validation Study for Breast Cancer
S.P. Somashekhar, MBBS, MCh(Onco), of the Manipal Comprehensive Cancer Centre, discusses a study to assess the performance of IBM's artificial intelligence platform in comparison to a multidisciplinary tumor board (Abstract S6-07).
Patricia A. Ganz, MD: Aromatase Inhibitors Data Review
Patricia A. Ganz, MD, of the UCLA Jonsson Comprehensive Cancer Center, summarizes two studies on using duloxetine for aromatase inhibitor–associated musculoskeletal symptoms, and aromatase inhibitors’ effect on endothelial function and heart disease (Abstracts S5-06 and S5-07).
Lisa A. Carey, MD, and Maki Tanioka, MD, on HER2+ Breast Cancer: Results From the CALGB 40601 Alliance Trial
Lisa A. Carey, MD, and Maki Tanioka, MD, both of the University of North Carolina, discuss study findings on weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer (Abstract S3-05).
Nikhil Wagle, MD, on Breast Cancer: Advances in Genomics
Nikhil Wagle, MD, Dana-Farber Cancer Institute, discusses the genomic sequencing of ER-positive metastatic breast cancer that has become resistant to therapies and the implications for the choice of next therapy, clinical trial eligibility, and novel drug targets (Abstract S1-01).
Jame Abraham, MD, on Hair Loss: SCALP Trial Results
Jame Abraham, MD, of the Cleveland Clinic, discusses findings of the Scalp Cooling Alopecia Prevention trial for patients with early-stage breast cancer (Abstract S5-02).
Pioneer in Cancer Immunology, Richmond T. Prehn, MD, Dies
Until 1957, the prevailing thought was that since cancers develop in normal patients, they are not recognized as foreign by the immune system. That changed when Richmond T. Prehn, MD, and his laboratory assistant, Joan Main, showed that tumors induced by chemical carcinogens in mice could...
Investigational Immunotherapy for Advanced Melanoma
The investigational immunotherapeutic IMC-20D7S was found to be well tolerated and somewhat active in patients with advanced melanoma, including one complete response, according to the results of a phase I/Ib trial reported by Danny N. Khalil, MD, PhD, and colleagues in Clinical Cancer Research....
SABCS 2016: Scalp-Cooling Device Safe and Effective in Reducing Chemotherapy-Induced Alopecia in Women With Breast Cancer
Although adjuvant chemotherapy decreases the risk of breast cancer recurrence, it is associated with distressing side effects, including hair loss. A prospective randomized trial evaluating the safety and efficacy of the Orbis Paxman Hair Loss Prevention System (OPHLPS), a scalp-cooling device that ...
Characteristics of HPV-Driven Nonoropharyngeal Squamous Cell Carcinomas of the Head and Neck
In a study reported in the Journal of Clinical Oncology, Chakravarthy et al found that human papillomavirus (HPV)-driven tumors accounted for 4.1% of nonoropharyngeal squamous cell carcinomas of the head and neck. HPV-positive tumors were associated with poorer survival and reduced...
Intensity-Modulated vs Three-Dimensional Conformal External-Beam Radiation Therapy in Locally Advanced Non–Small Cell Lung Cancer
In a secondary analysis from the NRG Oncology RTOG 0617 trial reported in the Journal of Clinical Oncology, Stephen G. Chun, MD, of the Department of Radiation Oncology at The University of Texas MD Anderson Cancer Center, and colleagues found that use of intensity-modulated vs three-dimensional...
George A. Komatsoulis, PhD, Joins CancerLinQ LLC as Chief of Bio-Informatics
CancerLinQ LLC has announced that George A. Komatsoulis, PhD, will be its first Chief of Bio-Informatics. This marks another step toward the organization’s goal of making the CancerLinQ® platform the premier system for unlocking patient data from millions of electronic health records, breaking...
Expect Questions About Cardiovascular Risk Factors Among Cancer Survivors
Reports of rare, but in some cases fatal, cardiac complications when the checkpoint inhibitors ipilimumab (Yervoy) and nivolumab (Opdivo) are used in combination should be taken seriously but should not scare patients away from potentially life-saving drugs, according to Javid J. Moslehi, MD. Dr....
Cardiac Complications in Patients Receiving Combination Checkpoint Inhibitors Are Rare but Can Be Fatal
Cardiovascular toxicities associated with cancer treatments are not new. What is new, and what has prompted recent articles in The New England Journal of Medicine,1,2 is the explosion of cancer therapies, which has dramatically changed the natural course of many cancers but can lead to cardiac,...
SABCS 2016: Women Experiencing Menopausal Symptoms Less Likely to Adhere to Medication in IBIS-1 Trial
Among women enrolled in the International Breast Cancer Intervention Study I (IBIS-I), those who had certain symptoms of menopause—nausea/vomiting and headaches—were significantly less likely to be adherent to the assigned medication 4.5 years after starting the treatment, according to...
NIH Statement on the Death of Former Congressman Melvin R. Laird
“I am greatly saddened by the death of former Congressman Melvin R. Laird, who, over the course of his distinguished career in public service, played a key role in advancing biomedical research and the mission of the National Institutes of Health (NIH). Our thoughts are with his family and the...
Overcoming the Physical, Emotional, and Financial Effects of Cancer
Although my diagnosis of stage IIIB melanoma 5 years ago came as a shock, in hindsight, it shouldn’t have been so surprising. I had noticed a small freckle-like lesion on my upper left thigh that had become itchy and occasionally bled, but it didn’t fit the ABCDE (Asymmetry, Border irregularity,...
SABCS 2016: Neoadjuvant Abemaciclib Treatment May Benefit Patients With Early-Stage Hormone Receptor–Positive, HER2-Negative Breast Cancer
Presurgical treatment with the investigational therapeutic abemaciclib, either alone or in combination with the aromatase inhibitor anastrozole, reduced levels of Ki67, a marker of cell proliferation, in hormone receptor–positive, HER2-negative breast cancer cells, compared with anastrozole...
Valerian
Scientific Names: Valeriana officinalis, Valeriana radix Common Names: Garden valerian, Indian valerian, Pacific valerian, garden heliotrope Overview A perennial flowering plant prevalent in Europe, Asia, and North America, valerian has a long medicinal history as a relaxant. Its potential as a...
SABCS 2016: BELLE-3 Trial of Buparlisib Plus Endocrine Therapy Meets Primary Endpoint of Progression-Free Survival in Breast Cancer Patients
The investigational PI3K inhibitor buparlisib, in combination with endocrine therapy, improved outcomes for patients with hormone receptor–positive advanced breast cancer that had progressed after treatment with everolimus (Afinitor) plus exemestane, according to data from the phase III...
SABCS 2016: Adding Veliparib to Chemotherapy Improved Response Rates Among Patients With BRCA-Mutant Breast Cancer
Adding the investigational poly ADP ribose polymerase (PARP) inhibitor veliparib to carboplatin and paclitaxel chemotherapy improved the overall response rate without increasing adverse events among patients who had locally recurrent or metastatic breast cancer with BRCA1 or BRCA2 mutations,...
2017 Oncology Meetings
JANUARY 2017 2017 Oncologic Emergency Medicine ConferenceJanuary 12-13 • Houston, Texas For more information: www.mdanderson.org/education-training/professional-education/cme-conference-management/conferences/oncologic-emergency-medicine-conference.html Advances in Medical and Surgical Management...
Sara A. Hurvitz, MD, on HR-Positive, HER2-Negative Breast Cancer: Results of the neoMONARCH Trial
Sara A. Hurvitz, MD, of the UCLA Jonsson Comprehensive Cancer Center, discusses findings on the biological effects of abemaciclib in a neoadjuvant study for postmenopausal patients (Abstract S4-06).
Profound Answers to Simple Questions
A few years ago, I had the good fortune to join a research team that intended to create a device to help dying children express their wants and needs despite communication challenges. The brain tumor team at SickKids [also known as The Hospital for Sick Children] had cared for several children...
Advocacy Group to Fund $1.6 Million in Grants for 8 Early Detection Ovarian Cancer Research Projects
Tina’s Wish, a nonprofit organization dedicated exclusively to funding scientific research for the early detection of ovarian cancer, recently announced its eight 2017–2018 individual grant recipients after soliciting proposals nationally for the first time. Researchers from Dana-Farber Cancer...
Team-Based Care in Oncology: National Cancer Institute and ASCO Launch Unique Project
In its November 2016 issue, the Journal of Oncology Practice (JOP) has published a special series that represents the results of a unique project launched in 2014 by ASCO and the National Cancer Institute (NCI) to heighten awareness of ways to enhance team-based care in oncology. Concerns about...
SABCS 2016: Radiation Therapy May Increase Complications in Breast Cancer Patients Receiving Implants
Radiotherapy increased complications and impaired patient-reported satisfaction with reconstructed breasts in breast cancer patients who received implant reconstruction, but not in those who received autologous reconstruction, according to data from a large, prospective, multicenter cohort study...
SABCS 2016: Adding Ibandronate to Hormone Therapy Did Not Improve Outcomes for Postmenopausal Breast Cancer Patients
Postmenopausal women with hormone receptor–positive early-stage breast cancer who received the bisphosphonate ibandronate (Boniva) in addition to adjuvant hormone therapy did not have improved disease-free survival outcomes, according to data from the phase III clinical trial TEAM IIB...
